The FDA Is Set to Decide on Moderna's Booster. Here's What It Means for the Stock.
Moderna's (NASDAQ: MRNA) stock has seen better days. Shares of the coronavirus vaccine giant have dropped 30% over the past month. Why the decline? Investors are concerned about diminished demand once the pandemic is over -- and as new COVID-19 treatments come to market. I've written about how that reaction was likely overdone.
Now, investors have turned their attention to something else: A regulatory meeting that could determine whether Moderna's booster candidate reaches the market in the coming days. A U.S. Food and Drug Administration (FDA) advisory committee meets today to discuss the candidate's fate. Could a positive decision lead to a rebound for the stock? Let's take a look.
Image source: Getty Images.
Source Fool.com
